MEDS
Sign in
Contact Us
THE SCIENCE

Recovery Runs on a Signal

Most men accept slower recovery, lighter sleep, and a body that gives back less as the price of getting older. It doesn't have to be.

‍Sermorelin is a prescription GHRH analog that signals your pituitary to release your own growth hormone rather than supplying it from outside.

Although Sermorelin was not originally developed for this use, licensed physicians may prescribe it as a personalized, compounded treatment when medically appropriate. Compounded meds aren't reviewed or approved by the FDA. Results vary.

Built to Work With the System, Not Around It

Upstream, Not Instead

Signals your pituitary to release growth hormone rather than supplying growth hormone directly. Individual response depends on pituitary function and clinical factors.

Your Brakes Stay On

Your body’s natural IGF-1 feedback continues to influence growth-hormone release. This does not eliminate the possibility of clinically inappropriate hormone levels, which is why MD monitoring is required.

The Gland Keeps Its Job

A releasing signal prompts the pituitary to produce growth hormone rather than replacing the hormone directly. The degree of response varies from person to person.

Timed to the Night

Typically taken at night to align with the body’s natural pattern of growth-hormone release. Timing does not guarantee a specific clinical response.
The Clinical Evidence

Restoration vs. Replacement

Supplying growth hormone from outside can quiet your own production. Sermorelin is designed to stimulate your body's own release.

Key Study: Nightly GHRH(1-29) in Older Adults (16-Week and 6-Month Trials)

In controlled studies of nightly bedtime GHRH(1-29) — the peptide family sermorelin belongs to — researchers tracked growth hormone output, IGF-1, and body composition in older adults over 16 weeks to six months. The studies summarized below evaluated injected GHRH(1-29), not T·TIME’s compounded sublingual ODT formulation. They are presented to explain the underlying mechanism and published research on this drug class. The reported results, percentages, and timelines should not be interpreted as expected outcomes from the T·TIME formulation. Individual response may differ.

Sermorelin vs. Administered Growth Hormone

How each raises growth hormone activity.

Metric Sermorelin (GHRH signal) Administered Growth Hormone
Nocturnal GH release

Sermorelin (GHRH signal)

Increased — from your own pituitary

Administered Growth Hormone

Supplied from outside
Increased — from your own pituitary Supplied from outside
IGF-1 (6-month data)

Sermorelin (GHRH signal)

Rose ~35–40% in men

Administered Growth Hormone

Rises to the dose given
Rose ~35–40% in men Rises to the dose given
Body composition

Sermorelin (GHRH signal)

Lean mass up, visceral fat down in studies

Administered Growth Hormone

Lean mass up, visceral fat down
Lean mass up, visceral fat down in studies Lean mass up, visceral fat down
Your own GH axis

Sermorelin (GHRH signal)

Preserved (system stays on)

Administered Growth Hormone

Suppressed (system stands down)
Preserved (system stays on) Suppressed (system stands down)
Mission Timeline

What Published Studies Measured Over Time

Growth-hormone signaling develops over time rather than acting like a stimulant. The stages below summarize when changes were measured in published studies of injected GHRH(1-29). They are not a prediction of whether an individual using T·TIME’s compounded formulation will notice results.

Month 1

Signal & Response (Endocrine Activation)

Week 1-2: The pituitary responds to the GHRH signal. In the studies that tracked it, nocturnal GH release increased in this window.
‍
‍Week 4: Biochemical response comes before subjective response. Most men feel nothing distinctive this early, and that is the expected pattern.

Month 2-3

The Measurable Window (Metabolic Read-Out)

IGF-1: This is where the longer trials picked up rises in IGF-1 — about 35–40% in men.
‍
‍Body composition: The six-month studies are where lean-mass and visceral-fat changes began to appear.

‍First review: Around the 3-month mark your physician reviews your response and adjusts, continues, or stops.

Month 4-6

Long-Term Vitality (Sustained Signalling)

Sustained treatment: The clearest body-composition signals in the research appeared across the full six months.

‍Ongoing monitoring: Growth-hormone signalling affects glucose handling, which is why this is monitored and not a supplement.

‍The honest ceiling: Sermorelin can only prompt what your pituitary can still produce — which is why response varies from man to man.
Data Comparison

Signal vs. Supply

Supplying growth hormone directly may reduce natural production. Sermorelin stimulates the pituitary instead. The table shows mechanistic differences; effects vary.

Sermorelin (a releasing signal) vs. Administered Growth Hormone (a supplied hormone)

Feature-level comparison across mechanism, control, and status.

Feature Sermorelin (Signal) Administered GH (Supply)
Primary action

Sermorelin (Signal)

Signals your own release

Administered GH (Supply)

Supplies the hormone directly
Signals your own release Supplies the hormone directly
GH profile

Sermorelin (Signal)

Pulsatile (natural burst pattern)

Administered GH (Supply)

Continuously elevated
Pulsatile (natural burst pattern) Continuously elevated
Feedback control

Sermorelin (Signal)

Self-limiting (feedback intact)

Administered GH (Supply)

Overridden
Self-limiting (feedback intact) Overridden
Upper limit

Sermorelin (Signal)

Your pituitary's own capacity

Administered GH (Supply)

The dose administered
Your pituitary's own capacity The dose administered
Regulatory status

Sermorelin (Signal)

Compounded, not FDA-approved

Administered GH (Supply)

FDA-approved products exist
Compounded, not FDA-approved FDA-approved products exist
TEST YOURSELF

Is Your Night Shift Clocking Out Early?

If one or more of these sounds like you, your overnight repair systems may be running in low gear. The decline is gradual, which is exactly why it gets written off as age. You may not feel "sick," but you know you aren't recovering the way you did. See if you recognise yourself in these common "warning lights":

The Long Bounce-Back

A hard session used to cost you a day; now it costs three, and you plan the week around the recovery.

Light Sleep, Heavy Mornings

You keep the same hours you always have, but you're not going as deep — and mornings feel like the night didn't count.

Same Work, Less Return

The training hasn't changed and the diet hasn't slipped, but your body isn't answering the way it used to.

Everything Heals Slowly

The tweaked shoulder and the rolled ankle that used to clear up on their own now linger for weeks.

You've Started Reading About Peptides

You've gone far enough into this to know the category exists — and to be wary of who's selling it.

The Verdict

If several of these describe you, that's worth a conversation with a licensed physician — not a self-diagnosis, and not proof of a deficiency. Age-related decline and true growth hormone deficiency are different things, and only a doctor can tell which one you're looking at.

It takes 2 minutes to see whether our protocol is appropriate for you.

Activate Your Protocol

See whether you're a candidate.

Don't let a slow decline set your trajectory.
T·TIME gives you a physician-reviewed, at-home path — and a straight answer either way.

The T·TIME  Launch Sequence:

Medical intake

Complete a secure medical questionnaire from home.

Physician review & prescription

A licensed U.S. physician reviews your intake. Not approved? Full refund.

Start
treatment

90-day supply of Sermorelin ODT, shipped to your door.

Safety & Clinical Disclaimers

  • Prescription Required: T·TIME is a prescription-only protocol. Eligibility is determined by a licensed physician based on your medical information and any testing considered necessary for your care.
    ‍
  • Compounding Notice: Sermorelin is a compounded medication and is not FDA-approved; it was previously marketed as Geref, and that approval was withdrawn in 2009. Compounded drugs are not reviewed by the FDA for safety, effectiveness, or quality prior to marketing.
    ‍
  • Off-Label Use: Compounded sermorelin is not FDA-approved for any indication. The adult uses discussed on this page have not been approved by the FDA and are prescribed only when a licensed physician determines treatment is medically appropriate. Sermorelin is not approved as a treatment for aging.
    ‍
  • Individual Results: Any timelines reflect findings from published clinical studies, which used injectable administration and differ from individual treatment. Individual results may vary based on baseline levels, age, and lifestyle, and some men will not respond.
    ‍
  • ‍Side Effects & Restrictions: Possible side effects include headache, flushing, dizziness, nausea, or altered taste; thyroid and glucose markers are monitored during treatment. Sermorelin is also prohibited in sport under the WADA Prohibited List, so tested athletes should not use it. Contact your T·TIME physician immediately if anything doesn't feel right.